Zacks Research Issues Pessimistic Outlook for COO Earnings

The Cooper Companies, Inc. (NASDAQ:COO) – Research analysts at Zacks Research decreased their Q2 2025 EPS estimates for Cooper Companies in a research report issued on Thursday, March 27th. Zacks Research analyst I. Bandyopadhyay now expects that the medical device company will earn $0.93 per share for the quarter, down from their previous estimate of $0.94. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies’ Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.20 EPS, Q1 2027 earnings at $1.10 EPS and FY2027 earnings at $4.85 EPS.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. The firm had revenue of $964.70 million during the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%.

Other analysts have also recently issued reports about the stock. Wells Fargo & Company increased their price target on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Robert W. Baird lowered their target price on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research note on Friday, March 7th. Citigroup cut their price target on Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. JPMorgan Chase & Co. decreased their price target on Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Finally, Morgan Stanley dropped their price objective on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a report on Friday, December 6th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $110.25.

Cooper Companies Stock Up 0.7 %

Shares of NASDAQ COO opened at $84.35 on Monday. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The company has a market cap of $16.87 billion, a price-to-earnings ratio of 43.26, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. Cooper Companies has a 12-month low of $77.05 and a 12-month high of $112.38. The firm’s 50-day simple moving average is $89.15 and its 200 day simple moving average is $97.03.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of COO. State Street Corp raised its stake in shares of Cooper Companies by 1.2% in the 3rd quarter. State Street Corp now owns 8,590,689 shares of the medical device company’s stock valued at $947,897,000 after purchasing an additional 104,521 shares during the period. T. Rowe Price Investment Management Inc. grew its holdings in shares of Cooper Companies by 2.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,678,965 shares of the medical device company’s stock worth $705,928,000 after buying an additional 155,233 shares in the last quarter. JPMorgan Chase & Co. raised its position in Cooper Companies by 1.5% in the 4th quarter. JPMorgan Chase & Co. now owns 5,004,523 shares of the medical device company’s stock valued at $460,066,000 after buying an additional 74,501 shares during the last quarter. Geode Capital Management LLC lifted its stake in Cooper Companies by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 4,906,463 shares of the medical device company’s stock valued at $449,907,000 after acquiring an additional 109,907 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its position in Cooper Companies by 14.6% during the 4th quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock worth $415,985,000 after acquiring an additional 574,899 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.